HOME>Our Products>Marketed & Pipeline Products for the treatments of central nervous system (CNS) disorders
Innovation today, healthier tomorrows

Marketed & Pipeline Products for the

treatments of central nervous system

(CNS) disorders

Over the past five years, Sunovion has reinforced its track record of bringing new Central Nervous System (CNS) therapies to market for people with serious medical conditions, including treatments to address schizophrenia, bipolar depression, and partial-onset seizures associated with epilepsy. During this time, the Company launched Latuda® (lurasidone HCI) and Aptiom® (eslicarbazepine acetate) in the U.S. and Canada, as well as LATUDA in Europe.

United States:

Aptiom.com

Latuda.com

Lunesta.com